T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

This study is testing a personalized immune cell therapy for people with bone or soft tissue sarcoma (cancers that develop in muscles, fat, nerves, or bone). The treatment uses immune cells (TILs) taken from the patient's own tumor, which are then genetically modified to produce a powerful immune-stimulating protein (IL-12) before being infused back into the body to attack the cancer. **You may be eligible if...** - You are 12 years old or older - You have been diagnosed with locally advanced or metastatic soft tissue or bone sarcoma - Your tumor can be surgically removed or biopsied to collect immune cells - You have received at least one prior systemic treatment for sarcoma - Your blood counts, kidney, and liver functions meet the required levels **You may NOT be eligible if...** - You have an active autoimmune disease - You have untreated cancer spread to the brain or spinal cord - You have had an organ transplant - You have HIV, active Hepatitis B or C, or a history of tuberculosis - You are pregnant or breastfeeding - You have had recent major surgery or a live vaccine Talk to your doctor to see if this trial is right for you.